Opiant Pharmaceuticals, Inc. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| WESTERN STANDARD LLC | 02/15/2023 | 424,080 | $8.60 M | 100.00% | 8.25% |
| APIS CAPITAL ADVISORS, LLC | 02/14/2023 | 214,000 | $4.34 M | 4.90% | 4.16% |
| MORGAN STANLEY | 02/14/2023 | 197,652 | $4.01 M | 2,640.98% | 3.85% |
| VANGUARD GROUP INC | 02/10/2023 | 190,773 | $3.87 M | 1.93% | 3.71% |
| RENAISSANCE TECHNOLOGIES LLC | 02/13/2023 | 146,415 | $2.97 M | -17.24% | 2.85% |
| WELLS FARGO & COMPANY/MN | 02/13/2023 | 136,814 | $2.77 M | -33.30% | 2.66% |
| DIMENSIONAL FUND ADVISORS LP | 02/09/2023 | 100,209 | $2.03 M | -10.92% | 1.95% |
| NEW YORK LIFE INVESTMENT MANAGEMENT LLC | 02/10/2023 | 61,912 | $1.26 M | 100.00% | 1.20% |
| CSS LLC/IL | 02/14/2023 | 61,349 | $1.24 M | 100.00% | 1.19% |
| PARKMAN HEALTHCARE PARTNERS LLC | 02/13/2023 | 59,943 | $1.22 M | -21.67% | 1.17% |
| RAMIUS ADVISORS LLC | 02/13/2023 | 55,298 | $1.12 M | 100.00% | 1.08% |
| YAKIRA CAPITAL MANAGEMENT, INC. | 02/10/2023 | 54,371 | $1.10 M | 100.00% | 1.06% |
| GEODE CAPITAL MANAGEMENT, LLC | 02/13/2023 | 48,591 | $985,000 | -0.28% | 0.95% |
| BLACK MAPLE CAPITAL MANAGEMENT LP | 02/14/2023 | 48,548 | $984,553 | 100.00% | 0.94% |
| ERGOTELES LLC | 02/14/2023 | 43,200 | $876,096 | 100.00% | 0.84% |
| SCHONFELD STRATEGIC ADVISORS LLC | 02/14/2023 | 42,300 | $857,844 | 100.00% | 0.82% |
| BLACKROCK INC. | 02/13/2023 | 39,425 | $799,539 | -1.24% | 0.77% |
| NORTHERN TRUST CORP | 02/13/2023 | 38,679 | $784,410 | -0.63% | 0.75% |
| GABELLI FUNDS LLC | 02/13/2023 | 37,119 | $752,773 | 100.00% | 0.72% |
| GABELLI & CO INVESTMENT ADVISERS, INC. | 02/15/2023 | 20,700 | $419,796 | 100.00% | 0.40% |
| TWO SIGMA ADVISERS, LP | 02/14/2023 | 18,600 | $377,208 | -20.51% | 0.36% |
| STATE STREET CORP | 05/15/2023 | 16,085 | $326,204 | 21.08% | 0.31% |
| FIFTH LANE CAPITAL, LP | 02/14/2023 | 15,000 | $304,200 | 100.00% | 0.29% |
| CITADEL ADVISORS LLC | 02/14/2023 | 14,169 | $287,347 | 100.00% | 0.28% |
| HARVEST MANAGEMENT LLC | 02/14/2023 | 12,000 | $243,360 | 100.00% | 0.23% |
| MARINER, LLC | 02/14/2023 | 10,550 | $214,000 | -22.14% | 0.21% |
| GAMCO INVESTORS, INC. ET AL | 02/15/2023 | 10,000 | $202,800 | 100.00% | 0.19% |
| ADVISOR GROUP HOLDINGS, INC. | 02/10/2023 | 5,500 | $111,000 | -5.17% | 0.11% |
| UBS GROUP AG | 02/08/2023 | 2,802 | $56,825 | 93.78% | 0.05% |
| LINDBROOK CAPITAL, LLC | 01/25/2023 | 2,000 | $40,560 | 300.00% | 0.04% |
| ROYAL BANK OF CANADA | 02/14/2023 | 1,200 | $24,000 | -2.68% | 0.02% |
| BANK OF AMERICA CORP /DE/ | 02/10/2023 | 1,070 | $21,700 | 100.00% | 0.02% |
| TOWER RESEARCH CAPITAL LLC (TRC) | 02/10/2023 | 744 | $15,000 | 71.43% | 0.01% |
| SPIRE WEALTH MANAGEMENT | 02/03/2023 | 500 | $10,000 | 0.00% | 0.01% |
| BALDWIN BROTHERS LLC/MA | 01/27/2023 | 300 | $6,084 | 100.00% | 0.01% |
| CORECAP ADVISORS, LLC | 02/10/2023 | 266 | $5,394 | 100.00% | 0.01% |
| FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 08/15/2024 | 180 | $3,650 | 0.00% | 0.00% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 02/03/2023 | 0 | $0 | -100.00% | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 01/30/2023 | 0 | $0 | 0.00% | 0.00% |
| ACADIAN ASSET MANAGEMENT LLC | 02/14/2023 | 0 | $0 | -100.00% | 0.00% |
| NATIONAL BANK OF CANADA /FI/ | 01/24/2023 | 0 | $0 | -100.00% | 0.00% |
| TWO SIGMA INVESTMENTS, LP | 02/14/2023 | 0 | $0 | -100.00% | 0.00% |
| PERRITT CAPITAL MANAGEMENT INC | 02/14/2023 | 0 | $0 | -100.00% | 0.00% |
| HEALTHINVEST PARTNERS AB | 02/14/2023 | 0 | $0 | -100.00% | 0.00% |
| BANK OF NEW YORK MELLON CORP | 02/14/2023 | 0 | $0 | -100.00% | 0.00% |
| STONEPINE CAPITAL MANAGEMENT, LLC | 02/14/2023 | 0 | $0 | -100.00% | 0.00% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT, INC. | 01/19/2023 | 0 | $0 | -100.00% | 0.00% |
| TREXQUANT INVESTMENT LP | 02/13/2023 | 0 | $0 | -100.00% | 0.00% |
Opiant Pharmaceuticals, Inc.institutional Ownership - FAQ's
During the previous two years, 7 institutional investors and hedge funds held shares of Opiant Pharmaceuticals, Inc.. The most heavily invested institutionals were:
RAMIUS ADVISORS LLC: 0
American Research & Management Co.: 300
Fondren Management LP: 137,000
Alambic Investment Management, L.P.: 0
Lenox Wealth Management, Inc.: 40
Advisor Group, Inc.: 6,600
41.50% of Opiant Pharmaceuticals, Inc. stock is owned by institutional investors.
Institutional investors have bought a total of 144,515 shares in the last 24 months. This purchase volume represents approximately $2.98 M in transactions.